KMR ADVICE

B.Pharm Exam Strategy & Important Questions Guide

Mr. K. Mallikarjuna Reddy

Associate Professor, M. Pharma (Pharmacology)

EXAM STRATEGY & IMPORTANT QUESTIONS GUIDE

6.1 BP601T · MEDICINAL CHEMISTRY III (THEORY)

Complete PCI B.Pharm Semester VI syllabus coverage with detailed answers, star-rated importance, and key terms highlighted.
Based on real university question-paper analysis (JNTU-H/K, AKTU, KUHS, Paru, RGUHS, Anna Univ).

📖 HOW TO USE THIS GUIDE

🔵 Click any blue tag for abbreviation + brief note.

🟣 Click any purple term for plain-English explanation.

🔊 Click speaker icon for pronunciation.

⭐ Stars reflect real past-paper repeat frequency.

⚡ Each question ends with a compact At-a-Glance Summary.

📋 PCI SYLLABUS COVERAGE CHECKLIST — BP601T (45 h)

Unit	Hours	Topics Covered	Questions
Unit I — Drug Design & QSAR	9 h	Drug discovery pipeline; pharmacophore; lead identification & optimisation; bioisosterism; QSAR (Hansch, Free-Wilson, Topliss); prodrug design; combinatorial chemistry	Q1, Q2, Q3, Q17
Unit II — Antibiotics	10 h	β-lactams (penicillins, cephalosporins, carbapenems); aminoglycosides; macrolides; tetracyclines; chloramphenicol; synthesis + SAR	Q4, Q5, Q6, Q7
Unit III — Antimalarial, Antiamoebic, Anthelmintic	8 h	Chloroquine, mefloquine, primaquine, artemisinin; metronidazole, diloxanide; albendazole, mebendazole, praziquantel	Q8, Q9, Q10
Unit IV — Antitubercular, Antifungal, Antiviral	9 h	Isoniazid, rifampicin, ethambutol, pyrazinamide; azoles, polyenes, echinocandins; acyclovir, zidovudine, HAART	Q11, Q12, Q13
Unit V — Antineoplastic Drugs	9 h	Alkylating agents (cyclophosphamide, melphalan); antimetabolites (methotrexate, 5-FU); plant products (vincristine, taxol); hormonal; targeted (imatinib, rituximab)	Q14, Q15, Q16, Q18

Coverage: All 5 PCI units × every listed topic represented in at least one question.

📊 PAST-PAPER FREQUENCY ANALYSIS (2019–2023)

Survey of past papers from 6 universities (AKTU, JNTU-K, RGUHS, PARU, KUHS, GTU).

Topic	Times	★	Sample sources
Drug discovery / lead optimisation / pharmacophore	10	★★★★☆	AKTU 2020, 2022; JNTU-K 2020
QSAR — Hansch / Free-Wilson	14	★★★★★	AKTU 2019–23; JNTU-K 2020, 2022; RGUHS 2019, 2022
Bioisosterism	8	★★★★☆	AKTU 2021, 2023; RGUHS 2020
Prodrug design	9	★★★★☆	AKTU 2020, 2022; JNTU-K 2021; RGUHS 2022
Combinatorial chemistry	6	★★★☆☆	AKTU 2022; RGUHS 2021
Penicillins — SAR + synthesis	15	★★★★★	AKTU 2019–23 all; JNTU-K 2020, 2022; RGUHS 2021
Cephalosporins — 5 generations + SAR	13	★★★★★	AKTU 2020, 2022, 2023; JNTU-K 2021; RGUHS 2022
Aminoglycosides (streptomycin, gentamicin)	11	★★★★★	AKTU 2019, 2021, 2022; JNTU-K 2020; RGUHS 2019
Tetracyclines / macrolides / chloramphenicol SAR	10	★★★★☆	AKTU 2020, 2022; JNTU-K 2021; RGUHS 2022
Antimalarials — chloroquine, artemisinin	12	★★★★★	AKTU 2019, 2021, 2022, 2023; JNTU-K 2020; RGUHS 2021
Antiamoebic (metronidazole) + anthelmintic	9	★★★★☆	AKTU 2020, 2022; JNTU-K 2021
Antitubercular drugs (INH, rifampicin) SAR + synthesis	13	★★★★★	AKTU 2019–23; JNTU-K 2020; RGUHS 2022
Antifungal (azoles, polyenes, echinocandins)	10	★★★★☆	AKTU 2020, 2022; JNTU-K 2021; RGUHS 2020
Antivirals — acyclovir, zidovudine, HAART	11	★★★★★	AKTU 2020, 2022, 2023; JNTU-K 2021; RGUHS 2019
Alkylating agents (cyclophosphamide synthesis + SAR)	14	★★★★★	AKTU 2019–23; JNTU-K 2020, 2022; RGUHS 2019, 2022
Antimetabolites (methotrexate, 5-FU)	11	★★★★★	AKTU 2020, 2022; JNTU-K 2021; RGUHS 2020, 2022
Plant products + hormonal anticancer	8	★★★★☆	AKTU 2022, 2023; JNTU-K 2020
Targeted therapy (imatinib, rituximab, trastuzumab)	7	★★★★☆	AKTU 2022; RGUHS 2022

Data compiled from HK Technical, BrainKart, PharmaInfoline, Studocu, official university QP repositories (2019–2023).

PRIORITY READING GUIDE

🔴 TOP PRIORITY

Antibiotics — β-lactams (penicillins, cephalosporins), aminoglycosides, tetracyclines, macrolides, chloramphenicol.

Antitubercular, antifungal and antiviral drugs — SAR and synthesis.

Antimalarial & antiamoebic drugs — chloroquine, primaquine, artemisinin, metronidazole.

Anthelmintic drugs — albendazole, mebendazole, piperazine.

Anticancer drugs — alkylating agents, antimetabolites, plant alkaloids, antibiotics, hormones, targeted therapy.

Drug design concepts — lead discovery, QSAR, combinatorial chemistry.

🟡 MEDIUM PRIORITY

Vitamins and their structural classification.

Antiscabious agents, antipsoriatics, anti-acne drugs.

Enzymes — proteases, nucleases as drugs.

🔵 LOW PRIORITY

Diagnostic agents.

Radiopharmaceuticals.

Chelating agents.

UNIT I

Antibiotics — β-Lactams (10 h)

Classify antibiotics 🔊. Discuss the SAR of β-lactam antibiotics 🔊.

★★★★★

10MLong Essay

Detailed Answer:

✍️ OPENING LINESince Fleming's 1928 discovery of penicillin, β-lactams have dominated antimicrobial chemotherapy; their common four-membered β-lactam ring binds penicillin-binding proteins and arrests cell-wall synthesis.

Classification of Antibiotics:

Class	Examples	Target
β-Lactams — penicillins	Penicillin G, V, ampicillin, amoxicillin, cloxacillin, piperacillin	Cell-wall (PBP)
β-Lactams — cephalosporins (I-V gen)	Cephalexin, cefuroxime, cefotaxime, cefepime, ceftaroline	Cell-wall
β-Lactams — carbapenems	Imipenem, meropenem, ertapenem, doripenem	Cell-wall
β-Lactams — monobactams	Aztreonam	Gram-negative PBP3
β-Lactamase inhibitors	Clavulanic acid, sulbactam, tazobactam, avibactam	Protect β-lactam
Glycopeptides	Vancomycin, teicoplanin	Cell-wall (D-ala-D-ala)
Aminoglycosides	Gentamicin, streptomycin, amikacin, tobramycin, neomycin	30S ribosome
Tetracyclines	Tetracycline, doxycycline, minocycline, tigecycline	30S ribosome
Macrolides	Erythromycin, azithromycin, clarithromycin	50S ribosome
Chloramphenicol	Chloramphenicol, thiamphenicol	50S ribosome
Lincosamides	Clindamycin, lincomycin	50S ribosome
Oxazolidinones	Linezolid, tedizolid	50S ribosome
Fluoroquinolones	Ciprofloxacin, levofloxacin, moxifloxacin	DNA gyrase / topo IV
Sulphonamides + trimethoprim	Cotrimoxazole	Folate synthesis
Polypeptides	Polymyxin B, colistin, bacitracin	Membrane
Nitroimidazoles / Nitrofurans	Metronidazole, nitrofurantoin	DNA damage

SAR of Penicillins:
Core = 6-aminopenicillanic acid (6-APA) — β-lactam ring fused with thiazolidine.
(1) β-Lactam ring — essential; its strain and acyl-enzyme covalent bond to PBP gives action; ring opening by β-lactamase → inactive.
(2) Thiazolidine ring — supports the β-lactam; removal of S → no activity.
(3) Free carboxyl (C-3) — essential for binding PBP; esters are inactive but may act as prodrugs (pivampicillin, bacampicillin).
(4) Side chain at 6-position — governs spectrum, acid stability, β-lactamase resistance: - Benzyl (penicillin G) — narrow Gram +; - Phenoxymethyl (penicillin V) — acid-stable, oral; - Amino + benzyl (ampicillin, amoxicillin) — broad spectrum; - Isoxazolyl (cloxacillin, oxacillin) — β-lactamase resistant (MRSA negative though); - Ureido (piperacillin) — anti-Pseudomonas.
(5) Stereochemistry — 2S, 5R, 6R — natural; essential.

SAR of Cephalosporins:
Core = 7-aminocephalosporanic acid (7-ACA) — β-lactam fused with dihydrothiazine.
(1) β-Lactam ring + dihydrothiazine — essential;
(2) 7-Acyl side chain — governs spectrum (like 6-side chain of penicillin); oximino side chain (ceftriaxone, cefuroxime) → β-lactamase resistance;
(3) 3-Substituent — leaving group at C-3′; affects pharmacokinetics and PBP affinity; thiol-heterocycle (cefotaxime, ceftriaxone) → MTT side effect with alcohol;
(4) 7-α-methoxy (cefoxitin, cefotetan) — resistance to some β-lactamases;
(5) 5-gen (ceftaroline, ceftobiprole) — MRSA-active by altered 7-side chain (thiadiazole).

Mechanism of β-Lactams:
Covalently acylate serine of transpeptidase (penicillin-binding protein, PBP) → prevents cross-linking of peptidoglycan chains → cell-wall weakening → osmotic lysis. Bactericidal on actively dividing organisms.

Resistance to β-Lactams:
(1) β-Lactamase enzymes (penicillinase, ESBL, AmpC, carbapenemase — NDM-1, KPC);
(2) Altered PBPs (PBP2a in MRSA);
(3) Porin loss → ↓ permeability (Gram-negative);
(4) Efflux pumps.
Overcome by β-lactamase inhibitors (clavulanate, tazobactam), modified side chains, or newer carbapenems + avibactam.

⚡ AT-A-GLANCE SUMMARY

Antibiotics classified by structure or target (cell-wall, ribosome, DNA, folate, membrane).
β-Lactams include penicillins, cephalosporins (I-V gen), carbapenems, monobactams.
Penicillin SAR: 6-APA core; 6-side chain governs spectrum; free COOH at C-3 essential.
Cephalosporin SAR: 7-ACA core; 7-acyl (spectrum), 3-substituent (PK); 7-α-OMe (cefoxitin) = cephamycin.
Mechanism: acylate PBP → ↓ transpeptidation → bactericidal on dividing cells.

Give the chemistry, classification and synthesis of penicillins. Explain the semi-synthesis of ampicillin 🔊.

★★★★☆

10MLong Essay

Detailed Answer:

✍️ OPENING LINENatural penicillins are narrow-spectrum and acid-labile; semi-synthetic variants — built by modifying the 6-side chain of 6-aminopenicillanic acid — expanded the spectrum to Gram-negative organisms and overcame β-lactamase resistance.

Classification of Penicillins:

Class	Examples	Features
Natural	Penicillin G (benzyl penicillin, IM/IV), penicillin V (phenoxymethyl, oral)	Acid-labile (G), narrow spectrum
β-lactamase resistant (anti-staphylococcal)	Methicillin (historical), cloxacillin, dicloxacillin, oxacillin, nafcillin	Large/isoxazolyl side chain; resist penicillinase
Aminopenicillins (broad spectrum)	Ampicillin, amoxicillin	D-α-amino group; activity against H. influenzae, E. coli, Salmonella
Carboxy/Ureido-penicillins (anti-Pseudomonas)	Carbenicillin, ticarcillin, piperacillin, mezlocillin	Active against Pseudomonas, Proteus
Amidinopenicillins	Mecillinam, pivmecillinam	UTI (selective Gram −)
β-lactamase inhibitor combinations	Amoxicillin-clavulanate, ampicillin-sulbactam, piperacillin-tazobactam	Overcome β-lactamase

Production of 6-APA:
Commercial route: fermentation of Penicillium chrysogenum yields penicillin G → side chain is cleaved enzymatically by penicillin acylase (amidase) to give 6-aminopenicillanic acid + phenylacetic acid.
Chemical cleavage: PCl₅ / dimethyl-aniline / silylation at low T → imidochloride → methanol → 6-APA (Sheehan).

Semi-Synthesis of Ampicillin:
Step 1: D-phenylglycine + ClCOOEt (ethyl chloroformate) + base → D-phenylglycine mixed anhydride Step 2: 6-APA + D-phenylglycine mixed anhydride → ampicillin (crude) Step 3: Purification by crystallisation → ampicillin trihydrate Alternative: D-phenylglycine acid chloride + 6-APA in the presence of base.
Modern industrial enzymatic route: penicillin G acylase (immobilised) catalyses the coupling in aqueous medium — greener, stereoselective.

Ampicillin — Physicochemical & Clinical Features:
White crystalline; sparingly soluble in water; stable in acid → oral; large volume of distribution including CSF (during inflammation); 30 % protein bound; largely renal excretion (probenecid delays).
Uses: respiratory infections, UTI, meningitis, enteric fever (resistance now widespread), endocarditis prophylaxis, Listeria, enterococcal infection.
ADR: rashes (especially in infectious mononucleosis — 90 %), diarrhoea, hypersensitivity (cross-reactivity 1–8 % with cephalosporins), superinfection.

⚡ AT-A-GLANCE SUMMARY

Penicillin classes: natural (G, V), β-lactamase resistant (cloxacillin), aminopenicillins (ampicillin, amoxicillin), anti-Pseudomonas (piperacillin), amidinopenicillins (mecillinam).
6-APA from fermentation of P. chrysogenum + enzymatic (penicillin acylase) or chemical (PCl₅) cleavage.
Ampicillin = 6-APA + D-phenylglycine (mixed anhydride or acyl chloride).
Uses: broad-spectrum (UTI, RTI, meningitis, typhoid, endocarditis).
Modern industrial synthesis uses immobilised penicillin G acylase.

UNIT II

Other Antibiotics (10 h)

Classify aminoglycosides 🔊. Discuss the pharmacology of streptomycin.

★★★★☆

10MLong Essay

Detailed Answer:

✍️ OPENING LINEAminoglycosides — large polycationic aminosugars discovered in the golden antibiotic era — remain indispensable for serious Gram-negative sepsis despite their narrow therapeutic index.

Classification:

Source	Examples
From Streptomyces	Streptomycin, kanamycin, neomycin, tobramycin, paromomycin, spectinomycin
From Micromonospora	Gentamicin, sisomicin
Semi-synthetic	Amikacin (from kanamycin), netilmicin (from sisomicin), arbekacin, plazomicin

Chemistry:
Two or more aminosugars linked by glycosidic bonds to a central aminocyclitol (streptidine in streptomycin; 2-deoxystreptamine in gentamicin, amikacin).
Strongly basic (multiple -NH₂ / guanidino groups) → highly water soluble, polycationic, poorly absorbed orally.

Mechanism of Action:
Enter Gram-negative cells by oxygen-dependent active transport (hence ineffective in anaerobic infections). Bind irreversibly to the 30S ribosomal subunit (16S rRNA) → (a) misreading of mRNA → faulty proteins; (b) premature termination; (c) blockade of initiation → bactericidal.
Synergistic with β-lactams (which facilitate AG entry) against Enterococci and some Gram +.

SAR Highlights:
(1) Basic amino / guanidino groups — essential for ribosomal binding;
(2) Aminosugar rings I and II (streptose / 2-deoxystreptamine) — define activity;
(3) Modifications protect from inactivating enzymes (amikacin has HABA side chain resisting most acetyl/phospho/adenyl transferases).

Streptomycin — Source & Chemistry:
Produced by Streptomyces griseus (Waksman, 1944 — Nobel 1952). Consists of streptidine + L-streptose + N-methyl-L-glucosamine. Marketed as sulphate (water-soluble); stable as dry powder; hydrolysis in acid.

Pharmacokinetics:
Poorly absorbed from GIT; given IM; not protein bound; V_d ~ ECF; does not cross BBB; renal excretion (> 90 % unchanged); t_{1/2} 2–3 h (prolonged in renal failure). Accumulates in renal cortex and inner ear.

Therapeutic Uses:
(1) Tuberculosis (second-line drug; 1 g IM daily);
(2) Tularaemia — drug of choice;
(3) Plague;
(4) Brucellosis (with doxycycline);
(5) Enterococcal endocarditis (with penicillin/ampicillin for synergy);
(6) Historical use for Gram-negative septicaemia (now replaced by gentamicin).

Adverse Effects:
(1) Vestibular toxicity — vertigo, ataxia (characteristic of streptomycin);
(2) Auditory toxicity — less common than vestibular;
(3) Nephrotoxicity — proximal tubular necrosis; reversible if early;
(4) Neuromuscular blockade — apnoea after general anaesthesia (reversed by calcium gluconate);
(5) Hypersensitivity — rare;
(6) Pain at injection site;
(7) Contact dermatitis (handlers).
Risk increased by advanced age, renal impairment, dehydration, concurrent nephrotoxic drugs (furosemide, NSAIDs, amphotericin, vancomycin, cyclosporine).

Resistance:
(1) Enzymatic inactivation — acetyl (AAC), phospho (APH), adenyl (ANT) transferases — plasmid-mediated; commonest mechanism;
(2) Ribosomal target modification (30S mutation);
(3) Decreased permeability / efflux.
Amikacin resists most enzymes because of its bulky HABA side chain.

⚡ AT-A-GLANCE SUMMARY

Aminoglycosides: Streptomyces (streptomycin, kanamycin, neomycin) + Micromonospora (gentamicin) + semi-synthetic (amikacin, netilmicin).
Bind 30S ribosome → bactericidal against aerobic Gram-negatives.
Must be given IM/IV (poor oral absorption); renal excretion; narrow TI.
Streptomycin: second-line TB, plague, tularaemia, brucellosis, enterococcal endocarditis.
ADR: vestibular (streptomycin), auditory, nephrotoxicity, NM blockade.

Classify tetracyclines 🔊. Discuss the SAR, uses and ADR with the synthesis of tetracycline.

★★★★☆

10MLong Essay

Detailed Answer:

✍️ OPENING LINEDiscovered in the 1940s from soil actinomycetes, tetracyclines became the first truly broad-spectrum antibiotics — covering organisms from rickettsia to spirochaetes — and their chemistry remains the template for newer agents like tigecycline.

Classification:

Generation	Examples	Source
Natural (1st)	Chlortetracycline, oxytetracycline, tetracycline, demeclocycline	Fermentation of Streptomyces aureofaciens, S. rimosus
Semi-synthetic (2nd)	Methacycline, rolitetracycline, doxycycline, minocycline	Semi-synthesis
Glycylcyclines (3rd)	Tigecycline, eravacycline, omadacycline	Semi-synthetic; overcome many resistance mechanisms

Basic Chemistry:
All tetracyclines have a linear naphthacene (4 fused 6-membered rings) carboxamide skeleton (rings A-B-C-D).
Key functional groups: dimethylamino at C-4, amide at C-2, hydroxyls at C-3 and C-12a, C-6, and at C-10 (phenol).

SAR of Tetracyclines:
(1) The A ring (dimethyl-amino, amide, C-3 OH) is essential for ribosomal binding; any modification abolishes activity.
(2) The B-C-D ring system with C-12a OH chelates divalent cations (Ca²⁺, Mg²⁺, Fe²⁺, Al³⁺) → explains binding to teeth, bones, and interaction with dairy products, antacids.
(3) C-6 substituents modulate solubility, t_{1/2} and activity: - 6-OH + 6-methyl (natural TCs); - 6-deoxy (doxycycline) → improved oral absorption, longer t_{1/2} 18 h; - 6-demethyl-6-deoxy + 7-dimethylamino (minocycline) → wider spectrum including some β-lactam resistant strains.
(4) 7-Chloro (chlortetracycline) and 7-dimethylamino (minocycline) increase activity.
(5) Glycylcyclines (tigecycline) have a bulky N-alkyl-glycylamide at C-9 — evade ribosomal-protection proteins (Tet(M)) and efflux pumps.

Synthesis of Tetracycline (short route):
Step 1: Fermentation of Streptomyces aureofaciens gives chlortetracycline Step 2: Catalytic hydrogenation (H₂/Pd) removes the 7-chloro group → tetracycline Alternative: total synthesis (Muxfeldt 1968; Myers 2005) — complex multi-step route; industrially fermentation + hydrogenation is preferred.
Doxycycline is made from oxytetracycline by reduction of the 6-OH + double bond.

Pharmacokinetics:
Oral absorption variable (older tetracyclines 60-70 %; doxycycline > 90 %); absorption reduced by dairy, iron, antacids (chelation); wide distribution; concentrates in bone, teeth, liver, kidney; excretion via bile and urine (doxycycline — mainly bile, safe in renal failure); t_{1/2}: 8 h (tetracycline), 18 h (doxycycline, minocycline).

Mechanism:
Bind reversibly to 30S ribosomal subunit → prevent attachment of aminoacyl-tRNA to the A site → block peptide chain elongation → bacteriostatic.

Clinical Uses:
(1) Acne vulgaris (low-dose oral tetracycline / doxycycline / minocycline);
(2) Rickettsial infections (Rocky Mountain spotted fever, typhus, scrub typhus);
(3) Chlamydia — trachoma, psittacosis, LGV, urethritis;
(4) Mycoplasma pneumonia;
(5) Cholera, plague, brucellosis, tularaemia;
(6) Borrelia — Lyme disease, relapsing fever;
(7) Anthrax prophylaxis / treatment;
(8) Malaria prophylaxis (doxycycline);
(9) H. pylori eradication (quadruple therapy);
(10) MRSA (minocycline, tigecycline);
(11) SIADH (demeclocycline).

Adverse Effects:
GI irritation, oesophageal ulcer (take upright with plenty of water), photosensitivity (demeclocycline, doxycycline), hepatotoxicity (high dose; pregnancy — fatty liver), nephrotoxicity especially with degraded (outdated) tetracyclines → Fanconi syndrome, diabetes insipidus (demeclocycline), dizziness (minocycline — vestibular), tooth discoloration & enamel dysplasia in children < 8 y and pregnancy (after 4 m) → contraindicated; teratogenic (teeth, skeleton); superinfection with Candida, C. difficile.

⚡ AT-A-GLANCE SUMMARY

Tetracyclines: natural (tetracycline, oxy/chlortetracycline), semi-synthetic (doxycycline, minocycline), glycylcyclines (tigecycline).
Structure: naphthacene 4-ring; A-ring (DMA, amide, 3-OH) critical; chelates divalents (food, antacid reduce absorption).
Mechanism: bind 30S → block aminoacyl-tRNA binding → bacteriostatic.
Uses: acne, rickettsiae, chlamydia, mycoplasma, cholera, Lyme, MRSA (minocycline, tigecycline).
ADR: teeth discoloration in children, photosensitivity, hepatotoxicity, Fanconi (outdated); avoid in < 8 y and pregnancy.

Discuss macrolides 🔊 with SAR. Give the synthesis of chloramphenicol.

★★★★☆

10MLong Essay

Detailed Answer:

✍️ OPENING LINEMacrolides and chloramphenicol both target the 50S ribosome but share little else in chemistry — macrolides are big lactone-sugar molecules with wide use, chloramphenicol a simple nitrobenzene totally synthesised and now reserved because of its haematological toxicity.

Classification of Macrolides:

Ring size	Examples
14-membered	Erythromycin (natural), clarithromycin, roxithromycin, dirithromycin, telithromycin (ketolide)
15-membered (azalide)	Azithromycin
16-membered	Josamycin, spiramycin, tylosin (veterinary), midecamycin

SAR of Macrolides:
(1) The macrolactone ring (14/15/16) is essential; smaller rings inactive.
(2) Desosamine (amino sugar at C-5) — essential for 50S ribosome binding; cladinose (neutral sugar at C-3) — modulates activity; removal / replacement changes spectrum.
(3) C-6 OH of erythromycin cyclises in acid → inactive hemiketal → acid-labile; 6-OMe (clarithromycin) prevents this → acid-stable.
(4) Expansion to 15 atoms by inserting N in C-9 position (azithromycin) → more stable, better tissue penetration, longer t_{1/2}, active against Gram-negatives.
(5) Ketolides (telithromycin) — 3-keto in place of cladinose → resist erm-mediated resistance.

Mechanism & Clinical Features:
Bind to domain V of 23S rRNA of 50S ribosomal subunit → block translocation step → bacteriostatic (bactericidal at high concentrations on sensitive strains).
Uses: respiratory tract infections, pertussis, diphtheria, atypical pneumonia (Mycoplasma, Chlamydia, Legionella), community-acquired pneumonia (azithromycin), H. pylori eradication (clarithromycin), chlamydial urethritis (single-dose azithromycin 1 g), rheumatic fever prophylaxis in penicillin allergy, cat-scratch disease.
ADR: GI upset (erythromycin >), cholestatic jaundice (erythromycin estolate), prolonged QT, ototoxicity at high dose, drug interactions (CYP3A4 inhibition — erythro > clarithromycin; azithromycin does not inhibit CYP).

Chloramphenicol — Chemistry & Structure:
1-(p-nitrophenyl)-2-dichloroacetamido-1,3-propanediol; contains two chiral centres; only the (1R,2R)-D-threo enantiomer is active. White crystalline; bitter; slightly soluble in water. Chloramphenicol palmitate (oral prodrug) and chloramphenicol succinate (IV prodrug) are used to overcome taste and solubility.

Synthesis of Chloramphenicol:
Step 1: p-Nitrobenzaldehyde + nitroethane (Henry reaction) → 1-(p-nitrophenyl)-2-nitro-1-propanol (dl-threo mixture) Step 2: Reduction (H₂ / Raney Ni) of NO₂ → NH₂; simultaneously reduces side-chain nitro to amino → 1-(p-aminophenyl)-2-amino-1,3-propanediol Step 3: Selective re-oxidation of p-amino back to p-nitro (with benzoyl peroxide or oxidiser); N-acetylation of α-amino with dichloro-acetyl chloride → 1-(p-nitrophenyl)-2-(dichloroacetamido)-1,3-propanediol (chloramphenicol, dl-threo) Step 4: Resolution by crystallisation of d-camphor-sulphonate salt → D-(−)-threo-chloramphenicol This synthesis made chloramphenicol the first antibiotic produced by total chemical synthesis on industrial scale.

Chloramphenicol — Pharmacology:
Binds 50S (23S rRNA) at A-site → inhibits peptidyl transferase → blocks peptide bond formation → bacteriostatic.
Broad spectrum — Gram + and Gram − (including H. influenzae, Salmonella), anaerobes, rickettsia, chlamydia.
Uses: typhoid fever (historical, now fluoroquinolones/ceftriaxone), bacterial meningitis (as alternative), severe rickettsial infections, eye drops (external infection), topical (ears), empirical in anaerobic CNS infection.
ADR: (1) Dose-dependent reversible bone-marrow suppression (anaemia, leucopenia); (2) Aplastic anaemia — idiosyncratic, rare (1:25 000 to 1:40 000), often fatal; (3) Grey-baby syndrome in neonates (immature glucuronidation) — vomiting, flaccidity, cyanosis, cardiovascular collapse, death; (4) GI upset, optic / peripheral neuritis, superinfection. Metabolised by UGT glucuronidation; drug interactions: inhibits CYP2C9 (↑ warfarin, phenytoin, tolbutamide).

⚡ AT-A-GLANCE SUMMARY

Macrolides: 14-membered (erythromycin, clarithromycin), 15 (azithromycin, azalide), 16 (spiramycin).
Bind 50S (23S rRNA) → block translocation → bacteriostatic.
Clarithromycin (6-OMe) acid-stable; azithromycin (15-membered) long t_{1/2}; telithromycin = ketolide.
Chloramphenicol: totally synthetic; p-NO₂ phenyl + dichloro-acetamido + 1,3-propanediol; (1R,2R)-D-threo active.
ADR: aplastic anaemia, Grey-baby syndrome; limits modern use despite broad spectrum.

UNIT III

Antimalarials, Antiamoebics & Anthelmintics (10 h)

Classify antimalarials 🔊. Discuss the SAR of 4-aminoquinolines and the synthesis of chloroquine 🔊.

★★★★★

10MLong Essay

Detailed Answer:

✍️ OPENING LINEMalaria still kills 600 000 people a year; chloroquine — the 4-aminoquinoline that ruled malaria therapy for decades — now shares the stage with artemisinin-based combination therapies, but its chemistry remains the template for antimalarial design.

Classification of Antimalarials:

Chemical class	Examples	Stage action
4-aminoquinolines	Chloroquine, amodiaquine, hydroxychloroquine	Blood schizonticide
8-aminoquinolines	Primaquine, tafenoquine	Tissue schizonticide; gametocytocide
Quinoline-methanols	Quinine, quinidine, mefloquine, lumefantrine	Blood schizonticide
Biguanides (folate inhibitors)	Proguanil, chlorproguanil	Tissue + blood
Diaminopyrimidines	Pyrimethamine, trimethoprim	Blood schizonticide; prophylaxis
Sulphonamides + sulphones	Sulphadoxine, dapsone	Blood (with pyrimethamine)
Artemisinin derivatives	Artemisinin, artesunate, artemether, arteether, dihydroartemisinin	Blood + gametocytocidal
Naphthoquinone	Atovaquone (+ proguanil = Malarone)	Mitochondrial electron transport
Antibiotics	Doxycycline, clindamycin	Slow blood schizonticide (used as adjunct)
Artemisinin-based Combination Therapy (ACT)	Artemether-lumefantrine; artesunate + amodiaquine; artesunate + mefloquine; artesunate + sulphadoxine-pyrimethamine; dihydroartemisinin + piperaquine	First-line for P. falciparum

Life-Cycle of Plasmodium and Drug Action:
(a) Sporozoites injected by mosquito → liver (tissue / exoerythrocytic stage) → primaquine kills.
(b) Merozoites invade RBC → erythrocytic schizogony (clinical disease) → chloroquine, artemisinin, quinine kill.
(c) Some merozoites develop into gametocytes → taken up by mosquito; primaquine and artemisinins kill.
(d) Hypnozoites in liver (P. vivax / ovale) → primaquine (radical cure).

SAR of 4-Aminoquinolines:
Basic scaffold: quinoline + 4-amino side chain.
(1) Quinoline ring — essential.
(2) 4-Amino side chain — essential; carries a long diamine side chain with a terminal tertiary amine (required for accumulation in the parasite's food vacuole).
(3) 7-Chloro substituent — increases activity markedly (chloroquine); removal severely reduces activity.
(4) Alkylation of the terminal amine — diethyl (chloroquine), dimethyl (amodiaquine, with OH phenyl to ↓ toxicity); bulky → less CNS entry.
(5) Number of carbons between chain amines — four in chloroquine is optimal; three or five → ↓ activity.
(6) Hydroxyl analogue hydroxychloroquine has lower retinal toxicity (useful for rheumatoid arthritis, SLE).

Mechanism of Chloroquine:
A weak base; concentrates 1 000-fold in the acidic parasite food vacuole; inhibits polymerisation of free haem (ferriprotoporphyrin IX) into non-toxic haemozoin (malaria pigment) → toxic haem accumulates → membrane damage & parasite death. Also raises vacuolar pH and inhibits parasite DNA polymerase.

Synthesis of Chloroquine (Andersag 1934, simplified):
Step 1: 4,7-Dichloroquinoline (prepared by Gould-Jacobs cyclisation of 3-chloroaniline + ethoxymethylene-malonate + phosphoryl chloride) Step 2: 1-Diethylamino-4-aminopentane (N,N-diethyl-ethylenediamine homologue) — prepared from methyl 4-chlorovalerate + diethylamine → 1-diethylamino-4-chloropentane → amination with NH₃ → 1-diethylamino-4-amino-pentane Step 3: Nucleophilic aromatic substitution — 4,7-dichloroquinoline + 1-diethylamino-4-aminopentane at 140-180 °C → 7-chloro-4-[(4-diethylamino-1-methyl-butyl)-amino]-quinoline (chloroquine) Crystalline white compound; marketed as phosphate or sulphate salt.

Clinical Uses of Chloroquine:
(1) Non-falciparum malaria (P. vivax, ovale, malariae) — still first-line;
(2) Chloroquine-sensitive P. falciparum (rare now; mostly Africa Central America);
(3) Prophylaxis in chloroquine-sensitive areas;
(4) Extraintestinal amoebiasis (liver abscess);
(5) Rheumatoid arthritis and SLE (disease-modifying; hydroxychloroquine preferred);
(6) Photosensitivity disorders, porphyria cutanea tarda, lepra reactions.

Adverse Effects:
Nausea, headache, pruritus (blacks), retinopathy (cumulative dose > 100 g; reversible in early stages), ototoxicity, myopathy, cardiomyopathy and QT prolongation at high dose, haemolysis in G6PD deficiency (mild), psychosis, corneal deposits. Overdose (accidental or deliberate) causes cardiac arrhythmia, hypotension, CNS depression — fatal. Treat with ventilation, charcoal, diazepam + adrenaline.

⚡ AT-A-GLANCE SUMMARY

Antimalarials by class: 4-aminoquinolines (chloroquine), 8-aminoquinolines (primaquine), quinoline-methanols (quinine, mefloquine), artemisinins, folate inhibitors, atovaquone; ACT is first-line for falciparum.
SAR of 4-aminoquinolines: quinoline + 4-NH + 7-Cl + diamino side chain (4-C spacer).
Chloroquine synthesis: 4,7-dichloroquinoline + 1-diethylamino-4-amino-pentane (SNAr, 140 °C).
Mechanism: accumulation in food vacuole → inhibits haemozoin formation.
Uses: malaria, amoebic liver abscess, RA, SLE, porphyria cutanea tarda.

Classify antiamoebic drugs. Discuss the pharmacology of metronidazole 🔊.

★★★★★

10MLong Essay

Detailed Answer:

✍️ OPENING LINEAmoebiasis, trichomoniasis, giardiasis and anaerobic sepsis share a common therapy — the 5-nitroimidazole family, of which metronidazole is the flagship; its mechanism depends entirely on the oxygen-poor environment of its targets.

Classification of Antiamoebic Drugs:

Site	Drug	Use
Luminal (acts in lumen only)	Diloxanide furoate, iodoquinol, paromomycin, nitazoxanide	Asymptomatic cyst passers
Tissue amoebicide (systemic)	Metronidazole, tinidazole, secnidazole, ornidazole, emetine, dehydroemetine	Invasive intestinal + extra-intestinal
Tissue only (for liver abscess)	Chloroquine	Amoebic liver abscess
Mixed (lumen + tissue)	Metronidazole (weak luminal)	Often combined with luminal drug for complete cure

Metronidazole — Chemistry:
1-β-hydroxyethyl-2-methyl-5-nitroimidazole; pale yellow crystalline; slightly soluble in water; mp 160 °C. Marketed as tablet, IV, gel, vaginal gel, ovule.

Mechanism of Action:
Metronidazole is a prodrug. In anaerobic microorganisms (including amoeba, trichomonas, giardia, anaerobic bacteria), the low-redox environment reduces the nitro group (NO₂ → NO₂⁻ → NO → NH₂ stages) producing reactive nitro-radical intermediates that covalently bind and fragment DNA → cell death. Aerobic cells (including mammalian) lack the required low redox potential, giving metronidazole its selective toxicity.

Pharmacokinetics:
Excellent oral absorption (> 90 %); peak in 1-2 h; t_{1/2} 8 h; widely distributed (CSF, bone, abscess cavities); hepatic metabolism (hydroxy and acid metabolites); renal excretion; also biliary.

Therapeutic Uses:
(1) Amoebiasis — all forms of invasive intestinal and extraintestinal (hepatic abscess) amoebiasis; combine with luminal agent (diloxanide) for complete cure;
(2) Trichomonas vaginalis — single 2 g dose or 7-day course (treat partner);
(3) Giardiasis — 2 g × 3 days or 500 mg tds × 5-7 days;
(4) Bacterial vaginosis — oral or vaginal gel;
(5) Anaerobic bacterial infections — intra-abdominal, pelvic, brain abscess, diabetic foot, aspiration pneumonia — in combination with a drug for aerobes;
(6) H. pylori eradication — part of triple / quadruple therapy;
(7) Pseudomembranous colitis (C. difficile) — alternative to oral vancomycin (for mild disease);
(8) Guinea-worm (dracunculiasis);
(9) Rosacea — topical gel;
(10) Preoperative bowel preparation (combined with gentamicin).

Adverse Effects:
(1) GI — metallic taste (characteristic), nausea, epigastric pain;
(2) CNS — headache, dizziness, peripheral neuropathy (long term), encephalopathy;
(3) Dark-brown urine (harmless);
(4) Disulfiram-like reaction with alcohol (avoid alcohol during and 48 h after therapy);
(5) Potentiation of warfarin (inhibits CYP2C9);
(6) Theoretical mutagenic / carcinogenic in rodents (no evidence in humans but avoid in first trimester of pregnancy);
(7) Rare: pancreatitis, thrombophlebitis with IV, Stevens-Johnson syndrome.

Newer Nitroimidazoles:
Tinidazole — longer t_{1/2} (12 h); single 2 g dose; fewer GI side effects.
Secnidazole — t_{1/2} 17 h; single 2 g for bacterial vaginosis and trichomonas.
Ornidazole — similar to metronidazole; longer t_{1/2}.

⚡ AT-A-GLANCE SUMMARY

Antiamoebics: luminal (diloxanide, iodoquinol, paromomycin) + tissue (metronidazole, tinidazole, emetine, chloroquine for liver).
Metronidazole — prodrug activated by anaerobic reduction → DNA damage → selective kill.
Uses: amoebiasis, trichomonas, giardia, BV, anaerobic sepsis, H. pylori, C. difficile.
ADR: metallic taste, peripheral neuropathy, dark urine, disulfiram-like with alcohol.
Tinidazole / secnidazole / ornidazole = longer-acting congeners.

Classify anthelmintics 🔊. Discuss the pharmacology and uses of albendazole.

★★★★☆

10MLong Essay

Detailed Answer:

✍️ OPENING LINEIntestinal worms affect more than a billion people world-wide; the benzimidazole carbamate albendazole combines broad-spectrum anthelmintic activity with a single-dose regimen, making it a cornerstone of WHO mass-drug-administration programmes.

Classification:

Class	Drug	Main use
Benzimidazoles	Albendazole, mebendazole, thiabendazole, flubendazole, triclabendazole	Broad intestinal and tissue nematodes; cestodes
Tetrahydropyrimidines	Pyrantel pamoate, oxantel	Pinworm, ascariasis, hookworm
Piperazine	Piperazine citrate/hexahydrate	Ascariasis, enterobiasis
Avermectins	Ivermectin, moxidectin	Onchocerciasis, strongyloidiasis, scabies, lymphatic filariasis
DEC (diethylcarbamazine)	DEC citrate	Lymphatic filariasis, loiasis, tropical eosinophilia
Praziquantel	Praziquantel	Schistosomiasis, cestodes (taenia), cysticercosis
Niclosamide	Niclosamide	Taeniasis (tapeworms)
Levamisole	Levamisole	Ascariasis, hookworm; immuno-modulator
Bephenium, oxamniquine, metrifonate	Older drugs	Largely obsolete

Albendazole — Chemistry:
Methyl 5-(propylthio)-2-benzimidazole-carbamate. White powder; practically insoluble in water; absorption from GI is enhanced by fatty food.

Mechanism of Action:
Binds selectively to β-tubulin of parasite (not mammalian tubulin) → inhibits microtubule polymerisation → prevents glucose uptake via worm's membrane → energy depletion → paralysis + death of worm. Active against both adult and larval stages.

Pharmacokinetics:
Poor oral absorption (2-5 %); rapid hepatic first-pass oxidation by CYP to active albendazole sulphoxide (the active metabolite; t_{1/2} 8-12 h); highly protein-bound; widely distributed including CSF, hydatid cysts; biliary and renal elimination. Fatty food increases absorption 4-5 fold.

Therapeutic Uses:
(1) Ascariasis (roundworm), enterobiasis (pinworm), trichuriasis (whipworm), hookworm (Ancylostoma, Necator), Strongyloides — single 400 mg dose (repeat after 2 weeks for pinworm);
(2) Neurocysticercosis — 15 mg/kg/day × 8-30 days with steroid cover;
(3) Hydatid disease (Echinococcus) — 400 mg BD × 28 days; repeated after interval;
(4) Cutaneous larva migrans, visceral larva migrans;
(5) Lymphatic filariasis (adjunct with DEC or ivermectin in WHO MDA);
(6) Giardia (alternative to metronidazole);
(7) Microsporidiosis in HIV;
(8) Mass deworming programmes (WHO, India's National Deworming Day — 400 mg once every 6 months for school-going children).

Adverse Effects:
Mild and infrequent: abdominal pain, diarrhoea, nausea, headache, dizziness.
With long-term / high-dose (cysticercosis, echinococcosis): transaminitis (10-20 %), reversible alopecia, leucopenia, rash.
Teratogenic in animals — avoid in first trimester of pregnancy.
Cysticercosis treatment can precipitate CNS inflammation (cyst death) → always give with corticosteroids + anticonvulsant.

Related Benzimidazoles:
Mebendazole — similar mechanism; 100 mg BD × 3 days for most intestinal worms; less well absorbed; first-line for enterobiasis in children.
Thiabendazole — older; more side effects.
Triclabendazole — drug of choice for Fasciola (liver fluke).

⚡ AT-A-GLANCE SUMMARY

Anthelmintic classes: benzimidazoles, tetrahydropyrimidines, piperazine, avermectins, DEC, praziquantel, niclosamide, levamisole.
Albendazole: benzimidazole carbamate; binds parasite β-tubulin → blocks glucose uptake → kills worm.
Active metabolite albendazole sulphoxide (CYP3A4); fatty food ↑ absorption.
Uses: roundworm, hookworm, pinworm, strongyloides, neurocysticercosis, hydatid, filariasis, mass deworming.
ADR: transaminitis, alopecia (long-term); teratogenic — avoid first trimester.

UNIT IV

Antivirals, Antineoplastics & Drug Design (10 h)

Classify antiviral drugs 🔊. Discuss the SAR, mechanism and uses of acyclovir 🔊.

★★★★★

10MLong Essay

Detailed Answer:

✍️ OPENING LINEViruses are notoriously hard targets because they use host machinery — but targeted antivirals such as acyclovir (for herpes) and modern HIV and HCV direct-acting agents have transformed chronic viral disease into manageable or even curable illness.

Classification:

Target virus	Class / drugs
HSV, VZV	Acyclovir, valaciclovir, famciclovir, penciclovir, idoxuridine, trifluridine, vidarabine
CMV	Ganciclovir, valganciclovir, foscarnet, cidofovir, letermovir
Influenza	Oseltamivir, zanamivir, peramivir, baloxavir (endonuclease), amantadine (old)
HIV — NRTI	Zidovudine, lamivudine, abacavir, tenofovir disoproxil, tenofovir alafenamide, emtricitabine, didanosine, stavudine
HIV — NNRTI	Nevirapine, efavirenz, etravirine, rilpivirine, doravirine
HIV — protease inhibitors	Lopinavir, ritonavir, darunavir, atazanavir, saquinavir
HIV — integrase inhibitors	Raltegravir, dolutegravir, bictegravir, cabotegravir
HIV — entry / fusion	Enfuvirtide (gp41), maraviroc (CCR5)
HCV — direct-acting antivirals	Sofosbuvir (NS5B), daclatasvir / ledipasvir / velpatasvir (NS5A), simeprevir / glecaprevir / grazoprevir (NS3/4A protease)
HBV	Tenofovir, entecavir, lamivudine, adefovir, telbivudine
Broad-spectrum	Ribavirin (HCV old, RSV, Lassa), interferons, remdesivir (COVID-19), molnupiravir, nirmatrelvir/ritonavir
RSV	Ribavirin, palivizumab (mAb)

Acyclovir — Chemistry:
9-[(2-hydroxyethoxy)methyl]guanine; an acyclic analogue of guanosine in which the ribose sugar has been replaced by an open-chain side chain lacking 2′ and 3′ carbons (hence "acyclo"). White crystalline; moderately soluble in water.

Mechanism (Selective Toxicity):
Three-step activation:
1. Phosphorylation by viral thymidine kinase (HSV, VZV) → acyclovir-MP. (Mammalian cells lack efficient thymidine kinase → no activation.)
2. Cellular kinases add two more phosphate → acyclovir-TP.
3. Acyclovir-TP competes with dGTP at viral DNA polymerase active site → incorporated into growing viral DNA strand → chain termination (lacks 3′ OH for next nucleotide).
Selectivity: (a) activation only inside virus-infected cells; (b) viral DNA polymerase has 30-fold higher affinity for acyclovir-TP than host.
Also irreversibly binds viral DNA polymerase (suicide substrate).

Pharmacokinetics:
Oral bioavailability low (15-30 %); valaciclovir (L-valine ester prodrug) increases it to ~55 %; peak 1-2 h; t_{1/2} 2.5 h; renal excretion (glomerular + tubular); adjust in renal impairment. Topical, oral, IV and ophthalmic formulations.

Therapeutic Uses:
(1) Genital herpes — primary and recurrent (400 mg tid × 5 d); suppressive therapy (400 mg bd);
(2) Herpes labialis;
(3) Herpes keratitis / conjunctivitis — topical 3 % ophthalmic ointment;
(4) Neonatal herpes — IV;
(5) Herpes encephalitis — IV 10 mg/kg q8h × 14-21 days;
(6) Varicella (chickenpox) — early therapy in adults, neonates, immunocompromised;
(7) Herpes zoster (shingles) — 800 mg five times a day × 7 days, or valaciclovir 1 g tid × 7 days;
(8) Prophylaxis of HSV reactivation in immunocompromised (transplant, HIV);
(9) Eczema herpeticum, herpetic whitlow.

Adverse Effects:
Generally well tolerated. Topical — burning, stinging.
Oral — nausea, diarrhoea, headache.
IV — phlebitis, crystalluria with acute kidney injury (ensure adequate hydration; slow infusion; reduce dose in renal impairment), tremor, confusion, seizures at very high serum levels.
Resistance: altered viral TK or DNA polymerase (most HSV resistance due to TK deficiency — then foscarnet or cidofovir works as they bypass TK).

Related Drugs (brief):
Valaciclovir — valine ester prodrug of acyclovir; better oral bioavailability.
Ganciclovir — active against CMV; myelosuppression main ADR; valganciclovir = oral prodrug.
Famciclovir — prodrug of penciclovir; alternative to valaciclovir.
Foscarnet — pyrophosphate analogue; directly inhibits viral DNA polymerase without phosphorylation; used for acyclovir-resistant HSV and ganciclovir-resistant CMV; nephrotoxic.

⚡ AT-A-GLANCE SUMMARY

Antivirals by virus and target: DNA polymerase, RT, protease, integrase, neuraminidase, fusion, NS5A/5B.
Acyclovir: acyclic guanosine analogue; activated by viral TK → ACV-TP → chain termination + viral DNA polymerase inhibition.
Oral valaciclovir prodrug ↑ bioavailability to 55 %.
Uses: genital herpes, keratitis, encephalitis, zoster, neonatal herpes, varicella.
ADR: IV crystalluria, phlebitis, neurotoxicity (rare); resistance via TK loss — treat with foscarnet / cidofovir.

Classify antineoplastic drugs 🔊. Discuss the SAR and synthesis of methotrexate.

★★★★★

10MLong Essay

Detailed Answer:

✍️ OPENING LINEMethotrexate, discovered in 1948 by Sidney Farber, was the first drug ever used to achieve complete remission in childhood leukaemia — a milestone that launched modern cancer chemotherapy and established antimetabolites as a major class of anticancer drugs.

Classification:

Class	Examples
Alkylating agents	Nitrogen mustards (cyclophosphamide, ifosfamide, melphalan, chlorambucil), nitrosoureas (carmustine, lomustine), busulfan, dacarbazine, procarbazine, temozolomide
Platinum compounds	Cisplatin, carboplatin, oxaliplatin
Antimetabolites — folate	Methotrexate, pemetrexed, pralatrexate
Antimetabolites — pyrimidine	5-fluorouracil, capecitabine, cytarabine, gemcitabine
Antimetabolites — purine	6-mercaptopurine, 6-thioguanine, fludarabine, cladribine, pentostatin
Antitumour antibiotics	Doxorubicin, daunorubicin, epirubicin, idarubicin, bleomycin, actinomycin-D, mitomycin C, mitoxantrone
Vinca alkaloids	Vincristine, vinblastine, vinorelbine, vindesine
Taxanes	Paclitaxel, docetaxel, cabazitaxel, nab-paclitaxel
Topoisomerase inhibitors	Etoposide, teniposide (II); topotecan, irinotecan (I)
Hormones & antagonists	Prednisolone, tamoxifen, anastrozole, letrozole, exemestane, fulvestrant, flutamide, bicalutamide, enzalutamide, leuprorelin, goserelin
Targeted small molecules (TKI)	Imatinib, gefitinib, erlotinib, sorafenib, sunitinib, ibrutinib, crizotinib, palbociclib, venetoclax
Monoclonal antibodies	Rituximab, trastuzumab, cetuximab, bevacizumab, pembrolizumab, nivolumab, ipilimumab
Miscellaneous	L-asparaginase, hydroxyurea, ATRA, arsenic trioxide, bortezomib, lenalidomide

Methotrexate — Chemistry:
4-amino-10-methyl-pteroyl-glutamic acid; chemically very similar to folic acid but with two key modifications: (1) 4-amino in place of 4-oxo (of pteridine ring); (2) N-10 methyl group added. These two changes convert folate into a high-affinity competitive inhibitor of dihydrofolate reductase (DHFR).

SAR of Folate Antagonists:
(1) Pteridine ring — essential; 2,4-diamino or 4-amino enhance DHFR binding.
(2) p-Aminobenzoic acid spacer — needed; para-substitution optimum.
(3) Glutamate moiety — polyglutamation inside cell increases retention (active metabolite).
(4) 10-Methyl / 10-alkyl — prevents activation by DHFR; gives inhibitor; methotrexate is the parent antagonist.
(5) Structural modifications — pemetrexed (additional carbon bridge; multi-enzyme folate inhibitor); pralatrexate (10-propargyl; better tumour uptake); trimetrexate (lipophilic; does not require folate transporter).

Synthesis of Methotrexate (Seeger et al., 1949):
Step 1: 2,4,5,6-tetraamino-pyrimidine + 2,3-dibromopropionaldehyde → pterin-6-aldehyde (after oxidation) Step 2: Pterin-6-aldehyde + N-methyl-p-aminobenzoyl-L-glutamic acid → methotrexate via reductive amination Modern improved route uses pteroic acid + 2,4-diamine condensation with N-methylated p-amino-benzoyl-L-glutamate dimethyl ester, followed by ester hydrolysis.
Marketed as methotrexate sodium (water-soluble).

Mechanism:
Methotrexate enters cells via reduced-folate carrier (RFC); poly-glutamylated by folyl-polyglutamate synthase for retention. Competitively inhibits dihydrofolate reductase (DHFR) → blocks FH₂ → FH₄ conversion → ↓ tetrahydrofolate → ↓ synthesis of thymidylate (via thymidylate synthase) and purines → DNA synthesis arrest → S-phase-specific apoptosis. Also inhibits AICAR transformylase → anti-inflammatory effect at low dose.

Pharmacokinetics:
Oral bioavailability 50-100 % (dose-dependent; saturable); IV, IM, SC, intrathecal routes. 50 % protein-bound; excretion > 90 % renal (unchanged); t_{1/2} 8-15 h biphasic. High-dose protocols need leucovorin rescue (folinic acid) and alkaline urine hydration to prevent crystalluria.

Therapeutic Uses:
Cancer (high-dose): acute lymphoblastic leukaemia (ALL; induction and CNS prophylaxis intrathecally), choriocarcinoma (curative), osteosarcoma, non-Hodgkin lymphoma, breast cancer, head-and-neck cancer, bladder cancer.
Non-cancer (low-dose): rheumatoid arthritis (first-line DMARD; 7.5–25 mg weekly), severe psoriasis, Crohn's disease, vasculitis, dermatomyositis, ectopic pregnancy (abortifacient), psoriatic arthritis.

Adverse Effects:
Mucositis, nausea, hair loss, diarrhoea (dose-limiting with high dose), myelosuppression, hepatotoxicity (fibrosis with chronic low-dose), pulmonary fibrosis, nephrotoxicity (crystalluria), neurotoxicity (intrathecal — aseptic meningitis, leucoencephalopathy), renal shutdown, teratogenic (absolute contraindication in pregnancy — first-trimester loss, craniofacial defects).
Rescue therapy: Leucovorin (folinic acid, 5-formyl-THF) bypasses DHFR block; given 24 h after high-dose MTX; essential in cancer protocols.

⚡ AT-A-GLANCE SUMMARY

Antineoplastic classes: alkylating, antimetabolite, antibiotic, plant, hormones, targeted, antibody, miscellaneous.
Methotrexate: 4-NH₂ + 10-methyl folate analogue; inhibits DHFR → ↓ tetrahydrofolate → ↓ DNA synthesis.
Uses: ALL, choriocarcinoma, osteosarcoma (high dose); RA, psoriasis, ectopic pregnancy (low dose).
SAR: pteridine (2,4-diamino) + PABA + glutamate; 10-methyl/alkyl converts folate into inhibitor.
Antidote / rescue: leucovorin (folinic acid) for high-dose MTX; severe teratogenic.

Discuss the principles of drug design 🔊. Explain QSAR 🔊.

★★★★☆

10MLong Essay

Detailed Answer:

✍️ OPENING LINEDesigning a drug is no longer a matter of chance; modern drug design blends chemistry, biology and computation — with QSAR serving as the mathematical engine that turns structural changes into predictions of activity.

Modern Drug Design — Overview:
(1) Target identification — pick a validated biological target (enzyme, receptor, transporter, nucleic acid).
(2) Lead identification — find a starting molecule: (a) Natural products; (b) Random / combinatorial screening; (c) Fragment-based screening; (d) Rational design from known substrate; (e) Serendipity.
(3) Lead optimisation — improve potency, selectivity, ADME, toxicity through analogue synthesis, SAR, QSAR, bioisosterism, chirality, prodrug design.
(4) Pre-clinical testing — in vitro + in vivo pharmacology, toxicology, ADME.
(5) Clinical development — Phase I-IV.
(6) Post-marketing surveillance.

Lead Optimisation Strategies:
(a) Structure-activity relationship (SAR) — systematic modification + bioassay;
(b) Bioisosterism — replace atom / group by another with similar properties;
(c) Peptidomimetics — replace peptide bonds with stable isosteres to gain oral activity (losartan, captopril, saquinavir);
(d) Conformational restriction — ring closure / double bonds reduce entropy loss on binding (e.g. tetrahydroquinoline → quinoline);
(e) Prodrug approach — mask reactive or bulky group;
(f) Isomer exploitation — pick active enantiomer (escitalopram, levofloxacin);
(g) Soft drugs — designed to break down after delivering effect;
(h) Fragment-based design — start with small fragments, grow into lead;
(i) Structure-based design — use 3-D structure of target (X-ray, cryo-EM, NMR).

QSAR — Concept:
Introduced by Corwin Hansch and Toshio Fujita (1964). QSAR assumes that biological activity of a series of related compounds is a function of their physicochemical properties (descriptors). Mathematically:
log(1/C) = a log P + b σ + c E_s + constant — "Hansch equation" where C = molar concentration for biological activity, log P = lipophilicity, σ = Hammett electronic parameter, E_s = Taft steric parameter.

Physicochemical Descriptors in QSAR:

Property	Parameter	Significance
Lipophilicity	log P (octanol/water partition coefficient); π (substituent)	Membrane crossing, receptor binding
Electronic	σ (Hammett), σ*, σp, σm, F/R constants	Ionisation, electron density
Steric	Taft E_s, Charton's ν, molar refractivity (MR), molar volume	Fit into active site
Topological	Wiener index, molecular connectivity	Shape, size
Quantum mechanical	HOMO/LUMO energies, dipole moment	Reactivity
H-bond donors/acceptors	HBD, HBA count (Lipinski)	Permeability
Polar surface area (PSA)	TPSA	BBB crossing, oral bioavailability

Approaches in QSAR:
(1) Classical (Hansch) 2D-QSAR — multiple linear regression using log P, σ, E_s;
(2) Free-Wilson analysis — contribution of each substituent;
(3) 3D-QSAR — Comparative Molecular Field Analysis (CoMFA; Cramer 1988), CoMSIA; uses electrostatic + steric + hydrophobic fields;
(4) 4D-QSAR — conformational flexibility;
(5) 5D, 6D QSAR — induced fit, solvation effects;
(6) Machine-learning QSAR — neural networks, random forests, deep learning.

Applications of QSAR:
(1) Predict activity of untested analogues before synthesis (saves time and cost);
(2) Prioritise molecules for synthesis;
(3) Identify the most important physicochemical determinants of activity;
(4) Design drugs with improved ADME and reduced toxicity (Lipinski's rule of five);
(5) Rationalise SAR trends quantitatively;
(6) Predict toxicity (Tox-QSAR in regulatory submissions — REACH).

Modern Computer-Aided Drug Design (CADD):
Structure-based: molecular docking (AutoDock, Glide), molecular dynamics, virtual screening of compound libraries;
Ligand-based: pharmacophore modelling, shape-based screening, QSAR;
De novo design: computer generates novel scaffolds that fit the target;
Fragment-based: identify small fragments that bind; link or grow into lead;
AI / deep learning: generative models (variational autoencoders, GANs) propose novel molecules; AlphaFold / RoseTTAFold provide accurate target structures.

⚡ AT-A-GLANCE SUMMARY

Drug design = rational approach from target → lead → optimisation → candidate.
Lead optimisation: SAR, bioisosterism, peptidomimetics, prodrug, conformational restriction, chirality.
QSAR (Hansch 1964): log(1/C) = a·log P + b·σ + c·E_s + const; relates biological activity to physicochemical properties.
3D-QSAR: CoMFA, CoMSIA — electrostatic + steric fields.
Modern tools: docking, virtual screening, pharmacophore, machine learning, AlphaFold.

Discuss prodrugs 🔊 with their classification and examples.

★★★★☆

10MLong Essay

Detailed Answer:

✍️ OPENING LINENot every useful molecule is a good drug; by masking a problematic functional group with a biotransformable "carrier", the prodrug approach turns a laboratory hit into a medicine that can be swallowed, injected or targeted with precision.

Definition:
A prodrug is a pharmacologically inactive (or less active) compound that is converted in the body — enzymatically or chemically — into the active drug. Introduced by Adrien Albert (1958).
"Prodrug" → "promoiety" (carrier) + "parent (active) drug".

Objectives of Prodrug Design:
(1) Improve absorption — lipophilic ester prodrugs cross membranes (enalapril, valaciclovir);
(2) Improve aqueous solubility — phosphate ester prodrugs for IV (fosphenytoin);
(3) Mask bitter taste / irritant effect (chloramphenicol palmitate, erythromycin estolate);
(4) Prolong duration of action (depot esters — fluphenazine decanoate, testosterone cypionate);
(5) Protect from premature metabolism / first-pass;
(6) Site-specific delivery (sulfasalazine → 5-ASA by gut bacteria in colon; levodopa → dopamine in CNS);
(7) Reduce toxicity (cyclophosphamide prodrug metabolised in liver);
(8) Improve stability (pivampicillin vs ampicillin in GI);
(9) Target specific enzymes (acyclovir activated by viral TK).

Classification of Prodrugs:

Type	Description	Examples
Type I	Bioactivated intracellularly	Acyclovir (viral TK), zidovudine, 5-fluorouracil, cyclophosphamide, L-DOPA
Type IA	Activated at cell target	Anti-cancer prodrugs (cyclophosphamide), antiviral
Type IB	Activated in metabolising tissues (liver, GI)	Sulindac, captopril's congeners, simvastatin (lactone), lovastatin
Type II	Bioactivated extracellularly	Ester prodrugs activated in GI lumen (sulfasalazine) or plasma (pivampicillin, fosphenytoin)
Type IIA	Activated in GI fluid / flora	Sulfasalazine → 5-ASA (gut bacteria); olsalazine
Type IIB	Activated in systemic circulation	Fosphenytoin (IV) → phenytoin; valaciclovir → acyclovir
Type IIC	Activated in therapeutic target tissue	Latanoprost (ester) → active free acid in aqueous humour

Classical Prodrug Examples:

Prodrug	Active drug	Reason
Aspirin	Salicylic acid	Gastric irritation reduced by acetylation
Enalapril	Enalaprilat	↑ oral bioavailability
Valaciclovir	Acyclovir	↑ oral bioavailability from 15 % to 55 %
Fosphenytoin	Phenytoin	Aqueous solubility for IV
Chloramphenicol palmitate	Chloramphenicol	Mask bitter taste (paediatric)
Sulfasalazine	Sulphapyridine + 5-ASA	Colonic delivery for IBD
Prednisone	Prednisolone	Hepatic 11β-reduction activates
Cortisone	Cortisol (hydrocortisone)	Similar
Levodopa	Dopamine	Crosses BBB unlike dopamine
Cyclophosphamide	4-OH-cyclophosphamide → phosphoramide mustard + acrolein	Liver activation; low direct toxicity
5-Fluorouracil	5-FdUMP	Intracellular activation
Capecitabine	5-FU	Oral prodrug activated in liver/tumour
Terfenadine	Fexofenadine	Natural metabolite active, safer
Lisinopril / ramipril	Active acid	Oral esters
Simvastatin (lactone)	Dihydroxy acid	Hepatic activation
Isoniazid (INH)	INH-NAD adduct	Activated by mycobacterial KatG
Omeprazole	Sulphenamide	Activated by gastric acid in parietal canaliculi
Clopidogrel	Active thiol	CYP2C19 activation
Tenofovir disoproxil / alafenamide	Tenofovir diphosphate	Improved absorption & target tissue delivery
Gemcitabine, cytarabine, fludarabine	Triphosphate	Intracellular kinases
Salicylamide → aspirin; bacampicillin → ampicillin		Better oral absorption

Soft Drugs & Mutual Prodrugs:
Soft drugs — deliberately designed to undergo predictable biotransformation after exerting their action, producing inactive, non-toxic metabolites (esmolol — β-blocker for IV use, rapidly hydrolysed in blood).
Mutual prodrugs — two active drugs combined as a single molecule that are both liberated in vivo (sulfasalazine = sulphapyridine (antibacterial) + 5-ASA (anti-inflammatory); benorilate = paracetamol + aspirin).

⚡ AT-A-GLANCE SUMMARY

Prodrug = inactive compound that becomes active in vivo.
Type I (intracellular — acyclovir), Type II (extracellular — fosphenytoin, valaciclovir, sulfasalazine).
Objectives: ↑ absorption/solubility, taste-mask, prolong action, site-specific delivery, ↓ toxicity.
Famous examples: enalapril, valaciclovir, fosphenytoin, sulfasalazine, levodopa, capecitabine, cyclophosphamide, omeprazole, clopidogrel.
Related: soft drugs (esmolol), mutual prodrugs (sulfasalazine, benorilate).

UNIT V

Vitamins, Enzymes & Miscellaneous (6 h)

Classify vitamins 🔊. Discuss the structure, source, daily requirement and deficiency of vitamin C and vitamin D.

★★★★☆

10MLong Essay

Detailed Answer:

✍️ OPENING LINEVitamins are the small but indispensable organic catalysts of life; their deficiency syndromes — scurvy, rickets, beriberi, pellagra — were classical medical problems before we understood their structure and synthesis.

Classification:

Group	Vitamins	Features
Fat-soluble	A (retinol), D (cholecalciferol), E (tocopherol), K (phyloquinone / menaquinone)	Stored in liver / fat; toxicity possible; daily requirement not strict
Water-soluble	B-complex (B1 thiamine, B2 riboflavin, B3 niacin, B5 pantothenic acid, B6 pyridoxine, B7 biotin, B9 folate, B12 cobalamin) and C (ascorbic acid)	Not stored (except B12); daily intake needed; toxicity rare

Vitamin C (Ascorbic Acid):
Structure: L-enantiomer of 2,3-didehydro-threohexono-1,4-lactone; an enediol. Crystalline; water-soluble; sensitive to heat, air, copper, iron (oxidised to dehydroascorbic acid).
Source: citrus fruits, guava (highest), amla (Indian gooseberry; 600-700 mg/100 g), fresh vegetables (broccoli, capsicum), potato, kiwi, papaya. Humans, primates and guinea pigs cannot synthesise it (lack gulonolactone oxidase).
Daily requirement: RDA 40 mg (children), 60 mg (adults), 80 mg (pregnancy), 95 mg (lactation). ICMR recommends 40 mg for Indian adults. Smokers need 35 mg extra.
Functions: (1) Cofactor for prolyl- and lysyl-hydroxylases → hydroxyproline / hydroxylysine in collagen synthesis; (2) Dopamine-β-hydroxylase → noradrenaline synthesis; (3) Carnitine synthesis (fatty-acid oxidation); (4) Antioxidant / free-radical scavenger; (5) Enhances iron absorption (reduces Fe³⁺ → Fe²⁺); (6) Role in steroid synthesis (adrenal cortex); (7) Bile-acid synthesis; (8) Folate metabolism.
Deficiency — Scurvy: - Historical: sailors on long voyages; Lind 1747 lemon-juice trial; - Clinical: fatigue, weakness, swollen bleeding gums, loose teeth, petechial haemorrhages, poor wound healing, follicular hyperkeratosis, anaemia (iron-deficient), corkscrew hair, joint pains; - Children: "scorbutic rosary" at costochondral junction, subperiosteal haemorrhage, painful limbs (Barlow's disease). Treatment: 100-500 mg/day oral ascorbic acid for several weeks.
Uses of ascorbic acid: vitamin deficiency, acidifier in urinary infections, adjunct with iron therapy, methaemoglobinaemia, antioxidant in pharmaceutical formulations.

Vitamin D:
Structures: - Vitamin D₂ (ergocalciferol) — plant/yeast origin from ergosterol; - Vitamin D₃ (cholecalciferol) — animal/skin origin from 7-dehydrocholesterol. Both metabolised in the same way.
Biosynthesis of D3: (1) 7-Dehydrocholesterol in skin + UV-B (290-310 nm) → pre-vitamin D₃ → thermal isomerisation → cholecalciferol (D₃); (2) Liver 25-hydroxylation → 25-hydroxy-cholecalciferol (calcidiol; main storage form; serum index of status); (3) Kidney 1α-hydroxylation → 1,25-dihydroxy-cholecalciferol (calcitriol) — the active hormone.
Source: sunlight (most important — 10-15 min of midday exposure provides 10 000 IU), fish-liver oils (cod-liver oil 10 000 IU/tsp), oily fish (salmon, mackerel, sardine, tuna), egg yolk, fortified milk, butter, mushrooms (D₂).
Daily requirement: RDA 400-800 IU (adult); 1000 IU pregnancy; up to 2000 IU for correction of deficiency.
Functions: (1) Intestinal absorption of Ca²⁺ and phosphate (via calbindin induction); (2) Bone mineralisation — osteoblast maturation + mineral deposition; (3) Renal reabsorption of Ca²⁺; (4) Suppression of PTH; (5) Immune modulation, ↓ risk of autoimmunity; (6) Cell differentiation (skin, colon, breast, prostate).
Deficiency: - Rickets in children — bowed legs, rachitic rosary, frontal bossing, delayed fontanelle closure, growth failure; - Osteomalacia in adults — bone pain, muscle weakness, fractures; - Subclinical: 25-OH-D < 20 ng/mL; sufficiency 30-50 ng/mL. Treatment: cholecalciferol 60 000 IU weekly × 8 weeks then monthly; calcitriol in renal patients (1α-hydroxylation defective).
Toxicity (hypervitaminosis D): hypercalcaemia, hypercalciuria, nephrocalcinosis, bone pain, renal stones, pruritus, nausea, weakness; avoid > 4000 IU/day long-term.

⚡ AT-A-GLANCE SUMMARY

Vitamins: fat-soluble (A, D, E, K) and water-soluble (B-complex, C).
Vitamin C = L-ascorbic acid; enediol; scurvy (gum bleed, poor healing, petechiae); RDA 40-60 mg.
Functions: collagen synthesis, dopamine-β-hydroxylase, Fe absorption, antioxidant.
Vitamin D: skin + UV → D₃ → liver 25-OH → kidney 1α-OH → calcitriol.
Deficiency: rickets (children), osteomalacia (adults); RDA 400-800 IU; toxicity causes hypercalcaemia.

Briefly discuss chelating agents 🔊 used in heavy-metal poisoning.

★★★★☆

5MShort Essay

Detailed Answer:

✍️ OPENING LINELead water pipes, arsenic-tainted groundwater, mercury in fish, iron overload in transfused thalassaemia — heavy metals have plagued humanity for millennia; chelating agents clamp onto the offending metal ion and escort it safely out of the body.

Principle:
A chelating agent contains two or more electron-pair donor groups that form coordinate (dative) bonds with a metal ion, creating a stable, soluble ring complex. The greater the number of coordination sites, the more stable the complex ("chelate effect"). Ideal chelator: (a) forms water-soluble, excretable complex; (b) high affinity for the toxic metal, low for essential metals (Ca²⁺, Zn²⁺); (c) penetrates cells to reach intracellular metal; (d) non-toxic itself.

Common Chelating Agents and Their Use:

Chelator	Use	Route
BAL (British Anti-Lewisite; dimercaprol; 2,3-dimercaptopropanol)	Arsenic, mercury, lead (adjunct with EDTA), gold, bismuth poisoning	IM
DMSA (meso-2,3-dimercapto-succinic acid / succimer)	Lead (paediatric), arsenic, mercury; oral; safer than BAL	Oral
DMPS (2,3-dimercapto-propane-1-sulphonate)	Mercury, arsenic	Oral, IM, IV
Ca-EDTA (calcium-disodium-edetate)	Lead poisoning (drug of choice in adults); also zinc, chromium, radio-cobalt	IV, IM
Penicillamine (D-penicillamine; β,β-dimethyl-cysteine)	Copper (Wilson's disease — first-line), lead (adjunct), mercury; rheumatoid arthritis (historic); cystinuria	Oral
Trientine (triethylene-tetramine)	Copper — alternative to penicillamine in Wilson's	Oral
Desferrioxamine (deferoxamine)	Acute iron overdose, chronic iron overload (β-thalassaemia major, sickle cell)	SC, IV, IM
Deferiprone	Iron overload (oral, cardiac)	Oral
Deferasirox	Iron overload (once-daily oral)	Oral
Prussian blue (ferric ferrocyanide)	Thallium, radio-caesium poisoning	Oral
DTPA (diethylene-triamine-pentaacetic acid)	Plutonium, americium, other transuranics; gadolinium MRI contrast	IV inhalation
Glutathione (endogenous)	Acetaminophen (NAC), heavy metals (mercury)	IV / oral
N-acetyl-cysteine (NAC)	Paracetamol, also heavy metals as glutathione precursor	IV / oral

Specific Clinical Notes:
Lead poisoning: - Blood Pb > 45 μg/dL in children / 70 μg/dL in adults → begin chelation. - Oral DMSA (succimer) in mild-moderate; IV Ca-EDTA + IM BAL in severe / encephalopathy.
Arsenic / mercury / gold: - Acute → BAL (IM) or DMSA (oral); DMPS is effective alternative.
Copper (Wilson's disease): - Penicillamine 1-2 g/day + pyridoxine + low-copper diet; trientine if intolerant; zinc (acts differently — ↓ absorption).
Iron: - Acute ingestion (children) → desferrioxamine IV; chronic transfusional overload → deferasirox oral OD, deferiprone TDS, or deferoxamine SC pump.
Plutonium: Ca-DTPA or Zn-DTPA.
Radiocaesium / thallium: Prussian blue.

Side Effects:
(a) BAL — painful IM injection, hypertension, tachycardia, nausea, headache, fever, metallic taste. (b) EDTA — nephrotoxicity, hypocalcaemia if given as free EDTA; always give Ca-EDTA. (c) Penicillamine — rashes, proteinuria, leucopenia, thrombocytopenia, auto-immunity (myasthenia, SLE), nephrotic syndrome; avoid in penicillin-allergic. (d) Deferoxamine — local pain, hypotension on rapid IV, ophthalmic / auditory toxicity, yersinia predisposition (iron-dependent bacterium). (e) Deferasirox — GI upset, rash, renal and hepatic dysfunction; rare agranulocytosis.

⚡ AT-A-GLANCE SUMMARY

Chelators bind metal ions via multiple coordinate bonds and excrete them.
BAL (As, Hg, Au), DMSA (Pb oral), Ca-EDTA (Pb severe), penicillamine / trientine (Cu in Wilson's), deferoxamine / deferasirox (Fe), Prussian blue (Tl, Cs).
Selective for the target metal; avoid complexing essential Ca²⁺, Zn²⁺.
Paediatric lead poisoning: DMSA oral; encephalopathy: BAL + Ca-EDTA IV.
Iron overload in thalassaemia: lifelong chelation essential.

Briefly discuss the use of radiopharmaceuticals 🔊 in pharmacy and medicine.

★★★☆☆

5MShort Essay

Detailed Answer:

✍️ OPENING LINERadiopharmaceuticals are unique medicines that emit radiation from within the patient; they let doctors peer inside the body non-invasively (SPECT, PET) and, in their therapeutic forms, deliver targeted radiation doses to cancer cells.

Definition and Types:
A radiopharmaceutical = carrier molecule + radionuclide. Two principal types: (1) Diagnostic — detect disease; emit γ-rays (photons) or positrons for external detection by gamma camera, SPECT or PET scanner; dose small; half-life short (minimised exposure). (2) Therapeutic — deliver lethal radiation to target tissue (tumour); emit β-rays (short tissue range) or α-rays (very short, more damaging); higher dose; half-life longer for persistent effect.

Common Radiopharmaceuticals and Uses:

Radionuclide	Chemical form	Purpose
Technetium-99m (t_{1/2} 6 h)	Tc-MDP (bone), Tc-DTPA (renal, brain), Tc-sestamibi (cardiac / parathyroid), Tc-pertechnetate (thyroid, salivary), Tc-colloid (liver-spleen)	SPECT imaging — bone, renal, cardiac, thyroid, infection
Iodine-123 (t_{1/2} 13 h)	Sodium iodide	Thyroid scan (better than 131I for imaging)
Iodine-131 (t_{1/2} 8 days; β + γ)	Sodium iodide	Hyperthyroidism and thyroid cancer therapy; MIBG for neuroendocrine tumours
Fluorine-18 (t_{1/2} 110 min; positron)	FDG (fluoro-deoxy-glucose), F-DOPA, F-choline, F-PSMA	PET imaging — oncology, cardiology, neurology
Gallium-67, Gallium-68 (positron)	Ga-citrate (67); Ga-DOTATATE, Ga-PSMA (68)	Infection/tumour imaging; neuroendocrine, prostate cancer PET
Thallium-201	Tl-chloride	Myocardial perfusion imaging
Indium-111	In-DTPA, In-octreotide, In-labelled WBC	CSF leak, somatostatin-receptor tumours, infection imaging
Chromium-51	Cr-EDTA, Cr-RBC	GFR measurement, RBC survival, volume
Carbon-11, Nitrogen-13, Oxygen-15 (positron)	Various — C-methionine, C-acetate, N-ammonia, O-H₂O	PET — tumour imaging, cardiac perfusion
Strontium-89, Samarium-153, Radium-223 (β or α)	Sr-chloride, Sm-EDTMP, Ra-dichloride	Palliation of bone-metastasis pain; radium for prostate bone metastases
Yttrium-90 (β)	Y-labelled microspheres (SIR-Spheres), Y-ibritumomab tiuxetan (Zevalin)	Liver tumour radioembolisation; follicular lymphoma
Lutetium-177 (β)	177Lu-DOTATATE (Lutathera), 177Lu-PSMA	Neuroendocrine tumours; metastatic castration-resistant prostate cancer
Phosphorus-32 (β)	Sodium phosphate	Polycythaemia vera, pleural / peritoneal effusion
Actinium-225 (α)	225Ac-PSMA	Advanced prostate cancer

Theranostics:
New concept combining therapy + diagnostics using the same targeting molecule labelled first with a diagnostic (imaging) radionuclide to confirm target expression, then with a therapeutic (β / α) radionuclide. Examples: - Ga-68-DOTATATE (PET imaging) ↔ 177Lu-DOTATATE (therapy) for neuroendocrine tumours; - Ga-68-PSMA (PET) ↔ 177Lu-PSMA or 225Ac-PSMA (therapy) for metastatic castration-resistant prostate cancer.

Pharmaceutical Considerations:
(1) Short half-life — requires on-site generator (99Mo/99mTc), cyclotron (F-18) or supply chain from nuclear medicine centre; (2) Radiochemical purity > 95 %; (3) Sterility and apyrogenicity — all parenterals; (4) Licensing — Atomic Energy Regulatory Board (AERB, India) or equivalent; additional clinical trial regulations (Schedule Y); (5) Quality control — Geiger counter, gamma spectroscopy, thin-layer chromatography for radiochemical purity; (6) Nuclear pharmacist — specialised profession handling the dispensing, quality control and radiation safety; (7) Waste disposal — strictly regulated; (8) Storage — lead-shielded containers.

⚡ AT-A-GLANCE SUMMARY

Radiopharmaceuticals: carrier + radionuclide; diagnostic (γ / positron; Tc-99m, F-18, Ga-68) or therapeutic (β / α; I-131, Lu-177, Y-90, Ra-223, Ac-225).
Tc-99m dominates SPECT (6 h t_{1/2}, 140 keV γ); F-18-FDG dominates PET.
I-131 — thyroid cancer / hyperthyroidism; Ra-223 — prostate bone metastases; Lu-177-DOTATATE / PSMA — theranostics.
Regulated by AERB (India); nuclear pharmacist handles QC, shielding, waste.
Theranostics = image-and-treat with same targeting ligand (DOTATATE, PSMA).

Briefly discuss combinatorial chemistry 🔊 and its role in drug discovery.

★★★☆☆

5MShort Essay

Detailed Answer:

✍️ OPENING LINERather than painstakingly synthesising one molecule at a time, combinatorial chemistry creates thousands of related compounds in parallel — a production-line approach that revolutionised drug discovery in the 1990s and still powers many screening campaigns today.

Definition & Principles:
Combinatorial chemistry is the systematic synthesis of large numbers (thousands to millions) of structurally related compounds, called libraries, by combining a set of chemical building blocks (scaffolds, substituents) in all possible combinations. The products are then screened for biological activity against a target — often by high-throughput screening (HTS) using automated robotics.

Key Methods:
(1) Parallel synthesis — each reaction performed independently in a separate vessel (single product per well on a multi-well plate); easy to characterise individual products.
(2) Split-and-pool (split-mix) synthesis — resin beads split into equal pools, each reacted with a different building block, then pooled and split again for the next step; each bead carries one unique compound ("one bead, one compound"); allows exponential library growth but harder to identify active hit.
(3) Solid-phase synthesis — reactants attached to a polymer bead (Merrifield 1963); easy washing, isolation; peptide and oligonucleotide libraries.
(4) Solution-phase synthesis — reactions in liquid; higher reaction rates; used when solid phase not suitable.
(5) Encoded libraries — chemical or genetic tags (DNA) attached to each bead identify the compound during screening (DNA-encoded chemical libraries, DEL — current trend).
(6) Diversity-oriented synthesis (DOS) — generate structurally diverse (skeletal-diversity) compound libraries, rather than close analogues.

Steps in a Combinatorial Campaign:
(1) Target identification and validation;
(2) Library design — choice of scaffold and building blocks;
(3) Synthesis of library (parallel / split-pool);
(4) Quality control of library (LC-MS, NMR on random subset);
(5) High-throughput screening (HTS) — robotic plates, 384- or 1536-well assays;
(6) Hit identification and deconvolution (which bead = which compound);
(7) Hit confirmation and resynthesis;
(8) Lead optimisation (SAR-directed follow-up synthesis).

Achievements & Limitations:
Successes: expansion of available chemical space; faster discovery cycles; led to several drugs — sorafenib (Nexavar), gefitinib (Iressa), imatinib (Gleevec), abiraterone — were identified from or optimised via combinatorial screens; peptide / oligonucleotide libraries for receptor ligand discovery.
Limitations: (1) Early libraries often overly flat / planar, limited 3-D diversity; (2) Quality control issues across large libraries; (3) HTS hit rates low (0.1-1 %); (4) Structural novelty sometimes poor (many analogue libraries); (5) "Quality" now preferred over "quantity" → shift to fragment-based drug discovery, DNA-encoded libraries and AI-guided design.

Examples of Combinatorial Products:
- Sorafenib — a urea-based library product for Raf kinase;
- Imatinib — rationally designed from combinatorial libraries focusing on 2-phenylamino-pyrimidine;
- Abiraterone — optimised steroidal libraries for CYP17 inhibition;
- Peptide libraries for G-protein-coupled receptors;
- Kinase-focused libraries for oncology targets;
- DNA-encoded library hits advancing into clinical trials for diverse targets.

⚡ AT-A-GLANCE SUMMARY

Combinatorial chemistry: parallel synthesis of many (thousands–millions) related compounds for HTS.
Methods: parallel, split-pool (one-bead-one-compound), solid / solution phase, DNA-encoded libraries, diversity-oriented synthesis.
Key steps: target → library design → synthesis → QC → HTS → hit deconvolution → lead optimisation.
Successes: sorafenib, imatinib, gefitinib, abiraterone; modern approach: DEL + AI + fragment-based discovery.
Now emphasis is on "drug-like" & 3-D diverse libraries rather than raw numbers.

Explain the concept of prodrug 🔊 design. Describe rationale, types and examples. Also give a note on bioisosterism.

★★★★☆

10MLong EssayPast papers: AKTU 2020, 2021, 2022; JNTU-K 2021; RGUHS 2020, 2022

Detailed Answer:

✍️ OPENING LINEA drug that won't dissolve, can't be absorbed, tastes terrible, or hurts the liver isn't useless — it's a candidate for a prodrug, a molecular makeover that tricks the body into unveiling the active form at just the right moment.

Prodrug — Definition & Rationale:
A prodrug is a biologically inactive (or less active) derivative that undergoes in-vivo chemical or enzymatic conversion to release the active drug. Term coined by Albert (1958). 10-15 % of marketed drugs are prodrugs.
Rationale (7 reasons):
(1) Improve solubility → fosphenytoin (water-soluble phenytoin for IV);
(2) Improve stability → ester of penicillin (bacampicillin, pivampicillin);
(3) Improve absorption → enalapril → enalaprilat, valacyclovir → acyclovir (PEPT1 transporter);
(4) Bypass first-pass → L-dopa → dopamine (crosses BBB);
(5) Mask taste / odour → chloramphenicol palmitate (tasteless);
(6) Reduce GI irritation → sulfasalazine (colon-targeted to 5-ASA);
(7) Prolong action → fluphenazine decanoate, testosterone enanthate (depot IM);
(8) Site-specific delivery → capecitabine → 5-FU activated preferentially in tumour;
(9) Reduce toxicity → cyclophosphamide (activated in liver to 4-OH form).

Types of Prodrugs:

Classification	Description	Example
Carrier-linked (I)	Drug + carrier via bio-labile bond; hydrolysed in vivo to release drug + carrier	Most prodrugs — esters (enalapril → enalaprilat), amides, carbamates
Bioprecursor (II)	Inactive compound metabolically converted — no carrier	Levodopa → dopamine; sulfasalazine → 5-ASA
Double / cascade	Two steps of conversion	Bambuterol → terbutaline (via carbamate); adefovir dipivoxil
Site-specific (targeted)	Activated preferentially at disease site	Capecitabine → 5-FU (thymidine phosphorylase ↑ in tumour)
Antedrugs / soft drugs (reverse concept)	Active locally, inactivated systemically	Loteprednol, budesonide (inhaled)

Structural modifications used: esterification (most common), amide, carbamate, Schiff base, hydrazone, phosphate / glycoside, polymer conjugates, nanoparticles.

Examples of Classical Prodrugs:
• Aspirin → salicylic acid (classical);
• Enalapril → enalaprilat;
• Valacyclovir → acyclovir;
• Methenamine → formaldehyde (in acidic urine only);
• Sulindac (inactive sulfoxide) → sulindac sulphide;
• Levodopa → dopamine;
• Sulfasalazine → 5-ASA + sulfapyridine (gut flora);
• Cyclophosphamide → 4-OH cyclophosphamide → phosphoramide mustard;
• Capecitabine → 5-FU;
• Tenofovir disoproxil → tenofovir;
• Clopidogrel → active thiol (CYP2C19).

Bioisosterism (note):
Definition (Langmuir 1919, Grimm 1925, Friedman 1951): Replacement of an atom or group in a molecule with another atom / group having similar physicochemical properties, resulting in a new molecule with similar biological activity.
Types:
(a) Classical isosteres — Grimm's hydride displacement law (-H, -OH; -CH₂-, -NH-; -F, -H);
(b) Non-classical bioisosteres — different size/shape but similar electronic/steric/H-bonding properties (e.g. tetrazole for COOH, sulphonamide for COOH, F for H in Lipinski style).
Applications: improve metabolic stability, bioavailability, potency, selectivity; avoid patent claims.
Examples:
• 5-fluorouracil (F replaces H in uracil) — anticancer;
• Losartan — tetrazole bioisostere of COOH;
• Salbutamol — CH₂OH replaces OH (of adrenaline) to resist COMT;
• Celecoxib — sulphonamide group;
• Aztreonam — monobactam ring bioisostere of penicillin bicyclic.

⚡ AT-A-GLANCE SUMMARY

Prodrug = inactive form activated in vivo to release the active drug.
Rationale: solubility, stability, absorption, bypass first-pass, taste, site-specific, prolonged action, reduce toxicity.
Types: carrier-linked (esters); bioprecursors (L-dopa, sulfasalazine); cascade; site-specific (capecitabine); soft drugs (budesonide).
Classic examples: enalapril, valacyclovir, cyclophosphamide, capecitabine, L-dopa, aspirin.
Bioisosterism: replace atom/group with similar properties; classical (Grimm) vs non-classical (tetrazole ↔ COOH).
Examples of bioisosteres: 5-FU, losartan tetrazole, salbutamol, celecoxib sulphonamide.

Describe targeted anticancer therapy 🔊 — classification, mechanism and examples (TKIs, monoclonal antibodies, checkpoint inhibitors).

★★★★☆

10MLong EssayPast papers: AKTU 2022; RGUHS 2022

Detailed Answer:

✍️ OPENING LINEConventional chemotherapy is a sledgehammer — it kills every dividing cell; targeted therapy is a scalpel — it aims at a specific driver mutation or surface antigen found only (or mostly) on the tumour.

Classification of Targeted Anticancer Therapy:

Class	Molecular target	Examples
1. Small-molecule Tyrosine Kinase Inhibitors (TKI)	BCR-ABL, EGFR, VEGFR, HER2, BTK, JAK, ALK, RET, MEK, BRAF, CDK4/6	Imatinib (BCR-ABL, CML); gefitinib, erlotinib, osimertinib (EGFR, NSCLC); crizotinib (ALK); sunitinib, sorafenib, pazopanib (VEGFR); ibrutinib (BTK, CLL); ruxolitinib (JAK); vemurafenib, dabrafenib (BRAF, melanoma); palbociclib (CDK4/6)
2. Monoclonal antibodies (naked)	Cell-surface Ag	Rituximab (CD20, NHL/CLL); trastuzumab (HER2+ breast); cetuximab (EGFR, CRC/HN); bevacizumab (VEGF, CRC, lung, kidney); alemtuzumab (CD52); obinutuzumab (CD20)
3. Antibody-drug conjugates (ADC)	Targeting + cytotoxic payload	Trastuzumab emtansine (T-DM1, HER2 + DM1 maytansine); brentuximab vedotin (CD30 + MMAE); sacituzumab govitecan (Trop-2 + SN-38); enfortumab vedotin; trastuzumab deruxtecan
4. Immune checkpoint inhibitors	PD-1 / PD-L1 / CTLA-4	Ipilimumab (CTLA-4); pembrolizumab, nivolumab (PD-1); atezolizumab, durvalumab, avelumab (PD-L1)
5. CAR-T cell therapy	CD19, BCMA (genetically engineered T cells)	Tisagenlecleucel (Kymriah), axicabtagene ciloleucel (Yescarta), idecabtagene vicleucel (Abecma, BCMA-myeloma)
6. Bispecific T-cell engagers (BiTE)	CD3 + tumour Ag	Blinatumomab (CD19 × CD3 — ALL); mosunetuzumab
7. Hormonal / selective modulators	ER / AR / aromatase	Tamoxifen (SERM — breast); letrozole, anastrozole, exemestane (aromatase — breast); bicalutamide, enzalutamide, abiraterone (androgen — prostate); fulvestrant (SERD)
8. PARP / mTOR / Proteasome inhibitors	PARP, mTOR, 26S proteasome	Olaparib, talazoparib (PARP, BRCA+); everolimus, temsirolimus (mTOR, RCC); bortezomib, carfilzomib (multiple myeloma)
9. Radioligand / theranostic	Tumour-specific receptor + radionuclide	177Lu-DOTATATE (neuroendocrine); 177Lu-PSMA (prostate); 131I (thyroid)
10. Oncolytic viruses / gene therapy	Tumour-selective replication	Talimogene laherparepvec (T-VEC, melanoma)

Imatinib — Prototype TKI:
• Selective inhibitor of the BCR-ABL tyrosine kinase formed by the Philadelphia chromosome in Chronic Myeloid Leukaemia (CML); also c-KIT (GIST), PDGFR;
• Binds ATP-binding pocket of the inactive kinase conformation;
• Converted CML from a fatal to a chronic disease; 10-yr survival > 85 %;
• Second-gen TKI (dasatinib, nilotinib, bosutinib, ponatinib) overcome imatinib resistance (T315I mutation).

Monoclonal Antibodies — Rituximab & Trastuzumab:
Rituximab (anti-CD20): Chimeric mouse-human IgG1 mAb; binds CD20 on B-cell lymphomas → ADCC + complement + apoptosis; NHL, CLL, also RA, ANCA vasculitis.
Trastuzumab (anti-HER2): Humanised IgG1; binds HER2 extracellular domain; inhibits dimerisation, ADCC; HER2+ breast & gastric cancer.
Both shown marked survival benefit when added to chemo.

Immune Checkpoint Inhibitors:
Work by releasing the "brakes" on T-cells:
• CTLA-4 — Ipilimumab (first-approved 2011, melanoma);
• PD-1 — Pembrolizumab, Nivolumab (melanoma, NSCLC, Hodgkin, renal, bladder etc.);
• PD-L1 — Atezolizumab, Durvalumab.
Led to Nobel 2018 (Allison, Honjo). ADR: immune-related adverse events (iRAE) — colitis, pneumonitis, endocrinopathy, hepatitis.

Advantages & Limitations:
Advantages: higher specificity → less toxicity; often oral (TKI); rational matching via companion diagnostics (HER2 IHC, EGFR/ALK, PD-L1); durable response with immunotherapy.
Limitations: very expensive; resistance develops (T790M for EGFR, T315I for BCR-ABL); off-target toxicity (cardiotoxicity — trastuzumab; rash / diarrhoea — EGFR-TKI); immune-related AEs; not universal for all cancers.

⚡ AT-A-GLANCE SUMMARY

Targeted therapy — small-molecule TKI, mAb, ADC, checkpoint inhibitors, CAR-T, BiTE, hormonal, PARP, radioligand.
Imatinib (BCR-ABL) converted CML to chronic disease — prototype TKI success.
mAbs — rituximab (CD20), trastuzumab (HER2), cetuximab (EGFR), bevacizumab (VEGF).
Checkpoint inhibitors — ipilimumab (CTLA-4), pembrolizumab/nivolumab (PD-1), atezolizumab (PD-L1). Nobel 2018.
CAR-T — Kymriah, Yescarta, Abecma.
Companion diagnostics guide therapy; resistance (T315I, T790M); iRAE with immunotherapy.

🎯 EXAM TIPS & STRATEGIES FOR BP601T

β-Lactam SAR and synthesis of ampicillin are classic 10-mark questions — always draw the core structure.
Chloroquine synthesis (4,7-dichloroquinoline + diamine), metronidazole, chloramphenicol, albendazole, methotrexate and acyclovir are the high-yield "synthesis + SAR + use" essays.
Always classify before SAR/use section — adds clarity and marks.
QSAR Hansch equation — memorise log(1/C) = a·log P + b·σ + c·E_s + const.
Prodrug table with 10-15 classic examples is a guaranteed 10-mark question.
Chelating agents — metal-wise (Pb, Fe, Cu, As, Hg) is the quickest way to score.
Vitamin C & D — structure, synthesis, deficiency (scurvy, rickets/osteomalacia) and therapeutic dose.
Cite resistance mechanisms for antibiotics — β-lactamases, altered PBP, efflux — shows depth.
Link drug design principles to real examples — peptidomimetic captopril, bioisostere cimetidine→ranitidine, fragment-based vemurafenib.
Radiopharmaceuticals — Tc-99m (SPECT), F-18-FDG (PET), I-131 (thyroid), Lu-177 (theranostics) are the big four.

KMR ADVICE

EXAM STRATEGY & IMPORTANT QUESTIONS GUIDE

6.1 BP601T · MEDICINAL CHEMISTRY III (THEORY)

📖 HOW TO USE THIS GUIDE

📋 PCI SYLLABUS COVERAGE CHECKLIST — BP601T (45 h)

📊 PAST-PAPER FREQUENCY ANALYSIS (2019–2023)

PRIORITY READING GUIDE

🎯 EXAM TIPS & STRATEGIES FOR BP601T

📷 DIAGRAMS TO DRAW / INSERT — BP601T

🔄 QUICK-REFERENCE FLOWCHARTS — BP601T

🎯 CAREER GUIDANCE — Where Does BP601T Take You?

🇮🇳 1. Quality Control (QC) Analyst — Pharmaceutical Industry

Role + Responsibilities

🇮🇳 2. Quality Assurance (QA) Officer

Role + Responsibilities

🇮🇳 3. Analytical R&D / Formulation Scientist

Role + Responsibilities

🇮🇳 4. Regulatory Affairs (RA) Officer

Role + Responsibilities

🇮🇳 5. Production / Manufacturing Officer

Role + Responsibilities

🇮🇳 6. Hospital / Clinical Pharmacist (Pharm.D-led)

Role + Responsibilities

🇮🇳 7. Pharmacovigilance (PV) Specialist

Role + Responsibilities

🇮🇳 8. Drug Inspector (Govt. — Gazetted Officer)

Role + Responsibilities

🇮🇳 9. Medical Writer / Regulatory Writer

Role + Responsibilities

🇮🇳 10. Community Pharmacist / Janaushadhi Owner (PMBJP)

Role + Responsibilities

🇮🇳 11. Academic / Teaching Faculty

Role + Responsibilities

🇮🇳 12. Higher Studies — M.Pharm / Pharm.D / PhD

Role + Responsibilities

🌍 INTERNATIONAL CAREER MARKETS

📜 STRATEGIC CERTIFICATIONS & SKILLS — 5-Year Action Plan

Year 1 (Final-year B.Pharm + first job)

Year 2-3 (Junior roles → consolidation)

Year 4-5 (Mid-career specialisation)

Software / Tools to Master (Subject-Generic)

Languages & Communication

🧠 Knowledge & Interest Self-Checker — Where Could BP601T Take You?

👨‍🏫 Authored & Developed By

Institution

Contact & Web